INTRODUCTION
Metastatic carcinomas are the largest group of malignant tumors of the liver. The majority arise from bronchogenic, colorectal, prostate, breast, and pancreatic cancers. Ovarian serous carcinoma is the most common form of epithelial ovarian cancer, and accounts for 40% to 50% of all such tumors, which spread to vital organ parenchyma, such as the lung and liver, and occur in 2-3% of the patients. Furthermore, parenchymal liver metastasis from cystic ovarian adenocarcinoma is very rare (1) (2) (3) . The number of studies that have evaluated the benefit of hepatic resection of metachronous metastases from gynecologic cancer is very small, but recently some authors have reported that hepatic resection of metachronous metastases from gynecologic carcinoma can be performed safely, and may help prolong survival in carefully selected patients (4) . We report a case in which the resection of metastatic liver neoplasm from ovarian serous cystadenocarcinoma was done 7 yr after initial treatment.
CASE REPORT
A 48-yr-old oriental housewife was admitted to the Department of Surgery in Severance Hospital, Yonsei University College of Medicine with mild abdominal discomfort in the right lower quadrant. She had previously received total abdominal hysterectomy with bilateral salpingo-oophorectomy due to serous papillary carcinoma of both ovaries at another hospital in August 1993 and had received 6 cycles of chemotherapy with cisplatin and alkyloxan, after the surgical treatment. She had a history of a pulmonary tuberculosis 20 yr before, which was treated with medication. Her father died from laryngeal cancer and her elder sister had ovarian cancer. She visited a private clinic with mild abdominal discomfort and hepatic mass was detected by ultrasonographic examination. She was transferred to our hospital for further evaluation and treatment.
The patient complained of easy fatigability and right lower quadrant discomfort. Vital signs on admission showed blood pressure of 110/70 mmHg, body temperature 36.8℃, respiration rate 18/min, heart rate 80/min. The findings from physical examination was unremarkable, except slightly pale conjunctivae and operative scars on the lower midline area. She looked anemic, with a hemoglobin 9.8 g/dL, and hematocrit of 30.4%. Serum albumin, bilirubin, and aspartate aminotransferase (AST)/alanine aminotransferase (ALT) were all within the normal ranges. Alkaline phosphatase level was slightly increased at 146 IU/L. A tumor marker study showed alpha-fetoprotein (AFP) 0.97 IU/mL, carcinoembryonic anti-
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DISCUSSION
The liver is the commonest site of blood-borne metastases from the abdominal viscera, and the most frequent site for metastatic growths, other than the lymph nodes (5). Metastatic carcinoma occurs much more frequently in the liver than primary hepatocelluar carcinoma. Patients with metastatic involvement of the liver present with major symptoms, including hepatic pain, hepatomegaly, ascites, and jaundice. Anorexia and weight loss are almost constant findings. Hepatomegaly and hepatic tenderness are frequently noted and palpation may reveal a distinct nodularity of the liver in about half the cases. The alkaline phosphatase level is increased in over 80 percents of patients and the AST level is increased in approximately two-thirds of the patients. Serum AFP determination is a good tumor marker for primary hepatocelluar carcinoma but in metastatic carcinoma it is negative (6). Serial follow-up for the tumor markers of specific tumors, such as CEA, CA 19-9, and CA 125, is helpful for diagnosis. In our patient, the CA 125 level was highly elevated at 1,267 ng/mL and the CA 19-9 was also elevated at 106.1 U/mL. Although CA 125 can be observed in a variety of benign conditions and other nongynecologic malignancies, it is elevated in 80% of epithelial ovarian cancers. These tumor markers may be useful in helping to predict the potential for malignancy preoperatively. If elevated, they can be used to monitor the response to therapy and detect early recurrence (3) .
Imaging studies also play an important role in determining liver metastases. The hepatic metastatic tumor from cystic ovarian carcinoma may manifest as a well-defined cystic lesion or as a solid mass, and this solid mass shows delayed enhancement on contrast-enhanced CT imaging. Furthermore, rapid cystic formation and subcapsular extension is frequently seen (7) . CT findings of our patient were compatible with the above descriptions. The level of specific tumor marker of primary cancer was useful and imaging studies were very helpful for the diagnosis of metastatic lesions in the liver from ovarian serous cystadenocarcinoma.
Hepatic resection for a secondary malignant growth can be performed safely with a real possibility of cure in selected instances (8) . Surgical treatment of hepatic metastases should be considered only if (a) the control of the primary tumor is accomplished or anticipated, (b) there are no systemic or intraabdominal metastases, (c) the patient's condition is compatible with the major operative procedure, and (d) the extent of hepatic involvement is such that resection and total extirpation of the metastases is feasible (6) . Resection of hepatic metastases from carcinomas of the colon and rectum appear to extend the survival time in appropriately selected patients, and selection criteria have been widely published. Similar data for patients with hepatic metastases from primary sites other than the colon and rectum are lacking (9) . However, recently some authors have reported that hepatic resection of metachronous metastases from gynecologic carcinomas including ovarian serous cystadenocarcinoma could be performed safely and might help prolong survival in carefully selected patients (4, 10) .
Ovarian epithelial cancers spread primarily by exfoliation of cells into the peritoneal cavity, by lymphatic dissemination, and by hematogenous spread. The most common and earliest mode of dissemination of ovarian cancer is through the exfoliation of cells that implant along the surfaces of the peritoneal cavity. Therefore, metastases are typically seen on the posterior cul-de-sac, paracolic gutter, right hemidiaphragm, liver capsule, and the peritoneal surfaces of the intestines and their mesenteries, and the omentum. Hematogenous dissemination at the time of diagnosis is uncommon and liver metastases from epithelial ovarian cancers are less frequent than other ovarian cancers, for example, stromal tumors, sarcomas, and germ cell tumors (11) . Total of 224 cases of variable hepatic resection were performed for metastatic tumor from March 1986 to May 2000 in our hospital. Among them 77 cases were metastatic liver neoplasms from non-colorectal primary tumors (34.8%). There were only 2 cases of hepatic resection for metastases from ovarian cancer (0.9% of the total number of hepatic resections for metastatic tumors). Various chemotherapeutic agents have been found to be active against ovarian serous cystadenocarcinoma. This additional therapy is indicated for patients in which the disease is more poorly differentiated or in whom there are malignant cells either in the ascitic fluid or in peritoneal washings (1). Single-agent cisplatin or cisplatin-based combination therapy is the most effective regimen. Recently, paclitaxel (Taxol), a microtubule stabilizer, was found to have significant activity in many cancers, and reported to be the drug of choice in the treatment of patients with cancer of the ovary and Fallopian tube that are resistant to conventional chemotherapy (12) . Oliverio et al. reported the efficacy of paclitaxel in the second-line treatment of refractory and relapsed ovarian cancer patients. They concluded that this therapy is an acceptable treatment with a good safety profile, and can be safely administered at a dosage of 175 mg/m 2 (13) . For patients treated initially with platinum therapy, paclitaxel has therapeutic responses occurring in 20-36% of patients (1). Our patient had already received 6 cycles of chemotherapy with cisplatin and alkyloxan after the first operation for ovarian cancer. Although all resection margins were negative for malignancy, the pathologic diagnosis of the tumor was poorly-differentiated adenocarcinoma with areas of necrosis and lymphovascular invasion and the tumor extended to the soft tissue of the Glisson's capsule. So we performed adjuvant chemotherapy with paclitaxel after hepatic resection.
In summary we report a rare case in which hepatic resection was done for metastatic liver neoplasm from serous cystadenocarcinoma of the ovary. The patient should be carefully followed-up with physical examinations, serial blood cell counts, blood chemistry, imaging studies, and the eval-uation of tumor marker levels.
